Department of Gastroenterology, National Hospital Organization, Shinshu Ueda Medical Center, Ueda, Japan.
Department of Laboratory Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Ann Diagn Pathol. 2020 Oct;48:151587. doi: 10.1016/j.anndiagpath.2020.151587. Epub 2020 Aug 14.
Colon cancer stem cells (CSCs) are closely related to tumorigenesis and treatment response, and LGR5 is currently the most robust and reliable CSC marker in colorectal cancer (CRC). However, LGR5 expression in CRC tumor budding (TB) is not well understood. We examined the clinicopathological and prognostic significance of LGR5 in CRC TB. LGR5 expression was evaluated by RNAscope, a newly developed RNA in situ hybridization technique, using a tissue microarray consisting of 55 patient samples of TB in colon adenocarcinoma (CA) selected from the medical archives at our hospital. Patients were stratified into negative and positive LGR5 expression groups. Tumor-infiltrating lymphocytes (TILs) and histological grade were lower in the LGR5-positive group compared with the LGR5-negative group (P = .0407 and P = .0436, respectively). There was no significant difference in overall survival between the LGR5-positive group and the LGR5-negative group (log-rank test, P = .6931). LGR5 expression did not remain a predictor of prognosis in univariate analysis (OR = 0.84, 95% CI: 0.33-2.02, P = .6928). LGR5 expression may be affected by TILs, which have been demonstrated to be associated with worse prognosis in the budding area of CA and is an important potential marker of prognosis.
结直肠癌干细胞（CSCs）与肿瘤发生和治疗反应密切相关，LGR5 是目前结直肠癌（CRC）中最具活力和可靠的 CSC 标志物。然而，CRC 肿瘤芽（TB）中 LGR5 的表达尚不清楚。我们研究了 LGR5 在 CRC TB 中的临床病理和预后意义。使用我院病历库中选择的 55 例结肠腺癌（CA）TB 患者的组织微阵列，采用新开发的 RNA 原位杂交技术 RNAscope 评估 LGR5 的表达。将患者分为 LGR5 表达阴性和阳性组。与 LGR5 阴性组相比，LGR5 阳性组的肿瘤浸润淋巴细胞（TILs）和组织学分级较低（P=0.0407 和 P=0.0436）。LGR5 阳性组和 LGR5 阴性组之间的总生存期无显著差异（对数秩检验，P=0.6931）。单因素分析中，LGR5 表达不是预后的预测因素（OR=0.84，95%CI：0.33-2.02，P=0.6928）。LGR5 表达可能受 TILs 的影响，TILs 已被证明与 CA 芽状区域的预后较差相关，是预后的一个重要潜在标志物。
